Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 16/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425025 | 0.90 | NR1H2 (0.39) | NR1H2NR1H3 | |
| SCHEMBL3423969 | 0.89 | NR1H2 (0.37) | NR1H2NR1H3GPR119 | |
| SCHEMBL1751863 | 0.89 | NR1H2 (0.50) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL1750924 | 0.88 | NR1H2 (0.42) | NR1H2NR1H3 | |
| SCHEMBL1750386 | 0.88 | NR1H2 (0.40) | NR1H2NR1H3GPR119CA12CA9 | |
| SCHEMBL3427304 | 0.87 | NR1H2 (0.36) | NR1H2NR1H3GPR119CA12CA9 | |
| SCHEMBL1750913 | 0.87 | NR1H2 (0.41) | NR1H2NR1H3 | |
| SCHEMBL1750961 | 0.86 | NR1H2 (0.40) | NR1H2NR1H3GPR119CA12CA9 | |
| SCHEMBL1750963 | 0.86 | NR1H2 (0.40) | NR1H2NR1H3GPR119CA12CA9 | |
| SCHEMBL1751880 | 0.85 | NR1H2 (0.53) | NR1H2NR1H3CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753743-B1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-7968546-B2 | Pyridazinone kinase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20090130209-A1 | Novel Pyridazinone Derivatives | AVENTIS PHARMA S.A. (FR) | 2009-05-21 | — | — | US | disclosed |
| US-7507734-B2 | Pyridazinone derivatives | AVENTIS PHARMA S.A. (FR) | 2009-03-24 | — | — | US | disclosed |
| US-20070259870-A1 | Novel Pyridazinone Derivatives | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| EP-1753743-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-02-21 | — | — | EP | disclosed |
| EP-1751141-A1 | NOVEL PYRIDAZINONE DERIVATIVES AS INHIBITORS OF CDK2 | Aventis Pharma S.A. (FR) | 2007-02-14 | — | — | EP | disclosed |
| EP-1604988-A1 | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005111018-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005111019-A1 | NOVEL PYRIDAZINONE DERIVATIVES AS INHIBITORS OF CDK2 | AVENTIS PHARMA S.A. (FR) | 2005-11-24 | — | — | WO | disclosed |
| EP-1598348-A1 | Novel pyridazinone derivatives as inhibitors of CDK2 | Aventis Pharma Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | GSK3B, GSK3A, PDXK | NR1H2 1537/4885NR1H3 1436/4885GPR119 1512/4885 |
| US-20090130209-A1 | Novel Pyridazinone Derivatives | CDK2, CDK1, CDK20 | NR1H2 3166/4885NR1H3 3632/4885GPR119 3206/4885 |
| US-20070259870-A1 | Novel Pyridazinone Derivatives | CDK2, CDK1, CDK20 | NR1H2 3166/4885NR1H3 3632/4885GPR119 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.